证券代码：300653 证券简称：正海生物 公告编号：2025-036 股东会提示性公告 烟台正海生物科技股份有限公司 关于召开 2025 年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经烟台正海生物科技股份有限公司（以下简称"公司"）第四届董事会第八 次会议审议通过，决定于 2025 年 8 月 27 日（星期三）召开 2025 年第一次临时 股东会。公司已于 2025 年 8 月 5 日在巨潮资讯网（www.cninfo.com.cn）上披露 了《关于召开 2025 年第一次临时股东会的通知》（公告编号 2025-035），本次股 东会采用现场投票和网络投票相结合的方式召开，现将本次股东会的有关事宜再 次提示如下： 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第八次会议审议通过，决 定召开 2025 年第一次临时股东会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： （ ...

Company Overview - Zhenghai Biological Technology Co., Ltd. is located in Yantai Economic and Technological Development Zone, Shandong Province, established on October 22, 2003, and listed on May 16, 2017. The company specializes in the research, production, and sales of biological regenerative materials [1] - The main business revenue composition includes: 50.99% from meninges series products, 48.98% from oral repair membranes, and 0.03% from other supplementary products [1] Financial Performance - As of June 30, 2025, Zhenghai Biological reported operating revenue of 188 million yuan, a year-on-year decrease of 5.14%, and a net profit attributable to shareholders of 46.49 million yuan, a year-on-year decrease of 45.97% [2] - The company has cumulatively distributed 617 million yuan in dividends since its A-share listing, with 334 million yuan distributed over the past three years [3] Stock Performance - On August 25, the stock price of Zhenghai Biological increased by 2.07%, reaching 22.70 yuan per share, with a trading volume of 113 million yuan and a turnover rate of 2.81%, resulting in a total market capitalization of 4.086 billion yuan [1] - Year-to-date, the stock price has risen by 8.89%, with a 1.52% increase over the last five trading days, a 0.89% increase over the last twenty days, and a 12.38% increase over the last sixty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders is 16,800, a decrease of 0.89% from the previous period, with an average of 10,704 circulating shares per person, an increase of 0.90% [2] - Among the top ten circulating shareholders, Dongfanghong New Power Mixed A (000480) is the fourth largest with 1.2268 million shares, an increase of 526,800 shares from the previous period. Dongfanghong JD Big Data Mixed A (001564) is the sixth largest, a new shareholder with 656,000 shares [3]

Core Viewpoint - Zhenghai Biological's stock price has shown a slight increase, but the company is facing significant challenges with declining revenue and profits due to reliance on core products and slow progress in new product development [1] Company Overview - Zhenghai Biological specializes in the research, production, and sales of bio-regenerative materials, including oral repair membranes and absorbable dura (spinal) membranes, positioning itself as one of the early entrants in the regenerative medicine field within the Class III implantable medical device sector [1] Financial Performance - For the first half of 2025, the company reported a revenue decline of 5.14% to 187 million yuan, with a net profit attributable to shareholders of 46.49 million yuan, down 45.97% year-on-year [1] - The decline in performance is primarily attributed to a 19.38% drop in revenue from oral repair membranes, a 38.87% increase in sales expenses, and adjustments in tax rates [1] Product Dependency and Development - The company's core products remain heavily dependent on oral repair membranes and dura patches, while new products such as active biological bone have not yet achieved significant sales volume, and the progress of the research pipeline is slow [1] Market Activity - On August 15, 2025, the net outflow of main funds for Zhenghai Biological was 855,500 yuan, while the cumulative net inflow over the past five days was 9.20 million yuan [1]

Core Viewpoint - Zhenghai Biological is at a crossroads of transformation as its marketing expenses surged by 39%, yet it failed to achieve revenue growth, with a significant decline in net profit and core product revenues [4][5] Financial Performance - The company reported a 5.14% year-on-year decline in revenue to 187 million yuan, while net profit dropped by 45.97% to 46.49 million yuan, and non-recurring net profit fell by 46.77% to 40.28 million yuan [4][6] - The main reasons for the profit decline include a nearly 20% drop in oral repair membrane revenue, increased cost pressures, and changes in the external environment [4][6] Product Performance - The sales revenue of the brain membrane series products increased by 5.88% to 80.27 million yuan, becoming a rare highlight in the report, attributed to successful bids in multiple provincial alliances [6] - Conversely, the oral repair membrane business saw a revenue decline of 19.38% to 77.12 million yuan, with a decrease in gross margin by 1.63 percentage points to 85.98% [6][7] - The decline in oral repair membrane revenue is attributed to weak market demand, intensified competition, and continuous price reductions [6][7] Tax and Regulatory Impact - Starting January 1, 2025, the VAT on key raw materials for Zhenghai Biological's main products will increase from a simplified rate of 3% to a general rate of 13%, significantly eroding profit margins [7] Structural Issues - The company's revenue structure is heavily reliant on two main products, which account for over 80% of total revenue, making it vulnerable to market fluctuations [6][7] Marketing and Sales Strategy - In response to declining performance, the company increased its sales expenses to 71.18 million yuan, a 38.87% increase, primarily for market promotion and commercial support [8] - The sales expense ratio rose from 25.88% to 37.90%, while net profit margin decreased from 43.45% to 24.75%, indicating a mismatch between marketing investment and revenue generation [8][9] New Product Development - The company is pinning hopes on new products like active biological bone, which has not yet generated significant sales despite being registered for nearly three years [9][10] - Other in-development products are progressing slowly, with potential revenue contributions expected in 2-3 years, which may not address immediate financial pressures [10] International Expansion - The company is exploring international markets, which present significant potential but require higher standards for product quality, certification, and marketing capabilities [10]

Group 1 - The company, Zhenghai Biological, confirmed that its products, including absorbable dura mater (spinal) patches, are primarily used in neurosurgery for the repair of dura mater (spinal) defects caused by various reasons [2] - The company's dura mater series products are not specifically mentioned to be applicable in brain engineering, but they are designed for medical applications related to the nervous system [2] - The interaction took place on an investor communication platform, indicating active engagement with investors regarding product applications [2]

格隆汇8月14日丨正海生物(300653.SZ)在互动平台表示，公司目前尚未开展人工子宫产品的研发及合 作。 ...

Group 1 - The core viewpoint of the article highlights that Zhenghai Biological's products, specifically absorbable dura mater patches and dura mater patches, are primarily used in neurosurgery for the repair of dura mater defects caused by various reasons [1] Group 2 - The company's products are designed to address dura mater defects, indicating a focus on the neurosurgery market [1] - The application of these products suggests a potential growth area within the medical device industry, particularly in neurosurgical procedures [1]

Market Overview - The recombinant protein sector experienced a decline of 1.14%, ranking among the top losers in the concept sector as of the market close on August 12 [1] - Notable stocks within this sector that saw significant declines include HaiTe Bio, Kexing Pharmaceutical, and Huiyu Pharmaceutical, while 13 stocks recorded gains, with *ST WanFang, Zhenghai Bio, and Huabei Pharmaceutical leading the increases at 3.42%, 2.66%, and 2.08% respectively [1] Capital Flow - The recombinant protein sector faced a net outflow of 484 million yuan from major funds, with 32 stocks experiencing net outflows, and 8 stocks seeing outflows exceeding 30 million yuan [1] - HaiTe Bio led the outflows with a net withdrawal of 79.69 million yuan, followed by YiPinHong, Chengdu XianDao, and BeiDa Pharmaceutical with outflows of 72.64 million yuan, 64.49 million yuan, and 52.64 million yuan respectively [1] Top Gainers and Losers - The top gainers in the recombinant protein sector included DeZhan Health, HuaXi Bio, and BoRui Pharmaceutical, with net inflows of 68.21 million yuan, 24.69 million yuan, and 17.58 million yuan respectively [3] - The detailed outflow list highlights stocks such as HaiTe Bio (-8.67%), YiPinHong (-2.70%), and Chengdu XianDao (-2.88%) as the most affected by capital withdrawal [2]

Core Insights - Zhenghai Biological reported an increase in sales expenses primarily due to market promotion of active biological bones and targeted marketing in the oral sector [2] - The decline in revenue was mainly attributed to a decrease in income from the oral segment [2] - The company plans to continue focusing on its advantageous areas and consistently incubate new products to achieve stable revenue growth in the future [2]

Core Viewpoint - Zhenghai Biological responded to investor inquiries on August 11, indicating that the degradation behavior of its products is influenced by factors such as surgical techniques, implantation sites, and specific patient conditions [2] Group 1 - The company emphasizes the importance of various factors in the degradation behavior of its products [2]